Pathophysiology and therapeutic needs in nonobstructive hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable degree of morbidity, including daily life limitat...

Full description

Bibliographic Details

Main Authors:	Desai, Milind (Author) , Maurizi, Niccolo (Author) , Biagini, Elena (Author) , Charron, Philippe (Author) , Fernandes, Fabio (Author) , González-López, Esther (Author) , van Haelst, Paul L. (Author) , Haugaa, Kristina Hermann (Author) , Kramer, Christopher M. (Author) , Meder, Benjamin (Author) , Michels, Michelle (Author) , Owens, Anjali (Author) , Yuasa, Shinsuke (Author) , Elliott, Perry (Author)
Format:	Article (Journal)
Language:	English
Published:	November 2025
In:	JACC Heart failure Year: 2025, Volume: 13, Issue: 11, Pages: 1-20
ISSN:	2213-1787
DOI:	10.1016/j.jchf.2025.102658
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.jchf.2025.102658 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2213177925005864
Author Notes:	Milind Y. Desai, MD, MBA, Niccolo Maurizi, MD, Elena Biagini, MD, Philippe Charron, MD, PHD, Fabio Fernandes, MD, Esther González-López, MD, Paul L. van Haelst, MD, PHD, Kristina Hermann Haugaa, MD, Christopher M. Kramer, MD, Benjamin Meder, MD, Michelle Michels, MD, PHD, Anjali Owens, MD, Shinsuke Yuasa, MD, Perry Elliott, MBBS